253 related articles for article (PubMed ID: 30063802)
1. Emricasan (IDN-6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension.
Garcia-Tsao G; Fuchs M; Shiffman M; Borg BB; Pyrsopoulos N; Shetty K; Gallegos-Orozco JF; Reddy KR; Feyssa E; Chan JL; Yamashita M; Robinson JM; Spada AP; Hagerty DT; Bosch J
Hepatology; 2019 Feb; 69(2):717-728. PubMed ID: 30063802
[TBL] [Abstract][Full Text] [Related]
2. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension.
Garcia-Tsao G; Bosch J; Kayali Z; Harrison SA; Abdelmalek MF; Lawitz E; Satapathy SK; Ghabril M; Shiffman ML; Younes ZH; Thuluvath PJ; Berzigotti A; Albillos A; Robinson JM; Hagerty DT; Chan JL; Sanyal AJ;
J Hepatol; 2020 May; 72(5):885-895. PubMed ID: 31870950
[TBL] [Abstract][Full Text] [Related]
3. Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-Stage Liver Disease Scores Compared With Placebo.
Frenette CT; Morelli G; Shiffman ML; Frederick RT; Rubin RA; Fallon MB; Cheng JT; Cave M; Khaderi SA; Massoud O; Pyrsopoulos N; Park JS; Robinson JM; Yamashita M; Spada AP; Chan JL; Hagerty DT
Clin Gastroenterol Hepatol; 2019 Mar; 17(4):774-783.e4. PubMed ID: 29913280
[TBL] [Abstract][Full Text] [Related]
4. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension.
Afdhal N; Everson GT; Calleja JL; McCaughan GW; Bosch J; Brainard DM; McHutchison JG; De-Oertel S; An D; Charlton M; Reddy KR; Asselah T; Gane E; Curry MP; Forns X
J Viral Hepat; 2017 Oct; 24(10):823-831. PubMed ID: 28295923
[TBL] [Abstract][Full Text] [Related]
5. Emricasan, a pan-caspase inhibitor, improves survival and portal hypertension in a murine model of common bile-duct ligation.
Eguchi A; Koyama Y; Wree A; Johnson CD; Nakamura R; Povero D; Kneiber D; Tameda M; Contreras P; Spada A; Feldstein AE
J Mol Med (Berl); 2018 Jun; 96(6):575-583. PubMed ID: 29728708
[TBL] [Abstract][Full Text] [Related]
6. Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease.
Shiffman M; Freilich B; Vuppalanchi R; Watt K; Chan JL; Spada A; Hagerty DT; Schiff E
Aliment Pharmacol Ther; 2019 Jan; 49(1):64-73. PubMed ID: 30430605
[TBL] [Abstract][Full Text] [Related]
7. Non-invasive aspartate aminotransferase to platelet ratio index correlates well with invasive hepatic venous pressure gradient in cirrhosis.
Kirnake V; Arora A; Sharma P; Goyal M; Chawlani R; Toshniwal J; Kumar A
Indian J Gastroenterol; 2018 Jul; 37(4):335-341. PubMed ID: 30178093
[TBL] [Abstract][Full Text] [Related]
8. The impact of emricasan on chronic liver diseases: current data.
Lekakis V; Cholongitas E
Clin J Gastroenterol; 2022 Apr; 15(2):271-285. PubMed ID: 35000120
[TBL] [Abstract][Full Text] [Related]
9. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.
Abraldes JG; Albillos A; Bañares R; Turnes J; González R; García-Pagán JC; Bosch J
Gastroenterology; 2009 May; 136(5):1651-8. PubMed ID: 19208350
[TBL] [Abstract][Full Text] [Related]
10. Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension.
Chalasani N; Abdelmalek MF; Garcia-Tsao G; Vuppalanchi R; Alkhouri N; Rinella M; Noureddin M; Pyko M; Shiffman M; Sanyal A; Allgood A; Shlevin H; Horton R; Zomer E; Irish W; Goodman Z; Harrison SA; Traber PG;
Gastroenterology; 2020 Apr; 158(5):1334-1345.e5. PubMed ID: 31812510
[TBL] [Abstract][Full Text] [Related]
11. Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension.
Manolakopoulos S; Triantos C; Theodoropoulos J; Vlachogiannakos J; Kougioumtzan A; Papatheodoridis G; Tzourmakliotis D; Karamanolis D; Burroughs AK; Archimandritis A; Raptis S; Avgerinos A
J Hepatol; 2009 Sep; 51(3):468-74. PubMed ID: 19616339
[TBL] [Abstract][Full Text] [Related]
12. A phase 2 randomised controlled trial of serelaxin to lower portal pressure in cirrhosis (STOPP).
Gifford FJ; Dunne PDJ; Weir G; Ireland H; Graham C; Tuck S; Hayes PC; Fallowfield JA
Trials; 2020 Mar; 21(1):260. PubMed ID: 32164767
[TBL] [Abstract][Full Text] [Related]
13. A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis.
Bosch J; Chung C; Carrasco-Zevallos OM; Harrison SA; Abdelmalek MF; Shiffman ML; Rockey DC; Shanis Z; Juyal D; Pokkalla H; Le QH; Resnick M; Montalto M; Beck AH; Wapinski I; Han L; Jia C; Goodman Z; Afdhal N; Myers RP; Sanyal AJ
Hepatology; 2021 Dec; 74(6):3146-3160. PubMed ID: 34333790
[TBL] [Abstract][Full Text] [Related]
14. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis.
Barreyro FJ; Holod S; Finocchietto PV; Camino AM; Aquino JB; Avagnina A; Carreras MC; Poderoso JJ; Gores GJ
Liver Int; 2015 Mar; 35(3):953-66. PubMed ID: 24750664
[TBL] [Abstract][Full Text] [Related]
15. Acute and 14-day hepatic venous pressure gradient response to carvedilol and nebivolol in patients with liver cirrhosis.
Silkauskaitė V; Kupčinskas J; Pranculis A; Jonaitis L; Petrenkienė V; Kupčinskas L
Medicina (Kaunas); 2013; 49(11):467-73. PubMed ID: 24823927
[TBL] [Abstract][Full Text] [Related]
16. The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study.
Pinter M; Sieghart W; Reiberger T; Rohr-Udilova N; Ferlitsch A; Peck-Radosavljevic M
Aliment Pharmacol Ther; 2012 Jan; 35(1):83-91. PubMed ID: 22032637
[TBL] [Abstract][Full Text] [Related]
17. Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease.
Bassegoda O; Olivas P; Turco L; Mandorfer M; Serra-Burriel M; Tellez L; Kwanten W; Laroyenne A; Farcau O; Alvarado E; Moga L; Vuille-Lessard E; Fortea JI; Ibañez L; Tosetti G; Vanwolleghem T; Larrue H; Burgos-Santamaría D; Stefanescu H; Paternostro R; Cippitelli A; Lens S; Augustin S; Llop E; Laleman W; Trebicka J; Chang J; Masnou H; Zipprich A; Miceli F; Semmler G; Forns X; Primignani M; Bañares R; Puente A; Berzigotti A; Rautou PE; Villanueva C; Ginès P; Garcia-Pagan JC; Procopet B; Bureau C; Albillos A; Francque S; Reiberger T; Schepis F; Graupera I; Hernandez-Gea V
Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2276-2286.e6. PubMed ID: 34688952
[TBL] [Abstract][Full Text] [Related]
18. Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study.
Bishnu S; Ahammed SM; Sarkar A; Hembram J; Chatterjee S; Das K; Dhali GK; Chowdhury A; Das K
Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):54-59. PubMed ID: 29099421
[TBL] [Abstract][Full Text] [Related]
19. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.
Ripoll C; Groszmann R; Garcia-Tsao G; Grace N; Burroughs A; Planas R; Escorsell A; Garcia-Pagan JC; Makuch R; Patch D; Matloff DS; Bosch J;
Gastroenterology; 2007 Aug; 133(2):481-8. PubMed ID: 17681169
[TBL] [Abstract][Full Text] [Related]
20. NCX-1000, a nitric oxide-releasing derivative of UDCA, does not decrease portal pressure in patients with cirrhosis: results of a randomized, double-blind, dose-escalating study.
Berzigotti A; Bellot P; De Gottardi A; Garcia-Pagan JC; Gagnon C; Spénard J; Bosch J
Am J Gastroenterol; 2010 May; 105(5):1094-101. PubMed ID: 19920806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
